

15 July 2022

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

United States
505 Fifth Avenue
Third Floor
New York, NY 10017
USA

T +1 212 880 2060
F +1 212 880 2061

info@mesoblast.com
www.mesoblast.com

Subject: Results Study Title: Posting Related to Mesoblast Clinical Trial
#MSB-RA002 (EudraCT Number: 2012-0056674-61)

Sponsor Company: Mesoblast

Study Title: A double-blind, randomized, placebo-controlled, multi-center, dose escalation study of a single intravenous infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in the treatment of biologic-naïve patients with rheumatoid arthritis

To Whom It May Concern,

The study MSB-RA002 was planned to be conducted in Belgium, Croatia, Czech Republic, Estonia, Hungary, Latvia, Poland as well as Serbia. However, the study was never conducted, and no subjects were enrolled. Consequently, there are no study results to submit.

Please feel free to contact me at any time.

Regards,

Christopher James, PA.
VP, Head Clinical Operations

Cell: 610-715-1351
Email: Christopher.James@mesoblast.com
www.mesoblast.com